• 1
    Gandaglia G, Briganti A, Gontero P et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia. BJU Int 2013; 112: 432441
  • 2
    Nickel JC, Roehrborn CG, O'Leary MP et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol 2008; 54: 13791384
  • 3
    Untergasser G, Madesbacher S, Berger P. Benign prostatic hyperplasia: age-related tissue-remodeling. Exp Geront 2005; 40: 121128
  • 4
    Know YK, Choe MS, Seo KW et al. The effect of intraprostatic chronic inflammation on benign prostatic hyperplasia treatment. Korean J Urol 2010; 51: 266270
  • 5
    Vela Navarrete R, Garcia Cardoso JV, Barat A, Manzarbeitia F, LópezFarré A. BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol 2003; 44: 549555
  • 6
    Latil A, Libon C, Templier M et al. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro. BJU Int 2012; 110: 301307